Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ.

J Am Coll Cardiol. 2018 Oct 9;72(15):1856-1869. doi: 10.1016/j.jacc.2018.07.071. Review.

PMID:
30286929
2.

Antihyperglycemic Medications and Cardiovascular Risk Reduction.

Anderson SL, Marrs JC.

Eur Endocrinol. 2017 Aug;13(2):86-90. doi: 10.17925/EE.2017.13.02.86. Epub 2017 Aug 22. Review.

3.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Med. 2017 Jun;130(6S):S18-S29. doi: 10.1016/j.amjmed.2017.04.008. Review.

4.

The kidney and cardiovascular outcome trials.

Bloomgarden Z.

J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616.

PMID:
29031006
5.

The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.

Dey AK, Groenendyk J, Mehta NN, Gourgari E.

Clin Cardiol. 2019 Jan 12. doi: 10.1002/clc.23152. [Epub ahead of print] Review.

6.

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.

Scheen AJ.

Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588. Review.

7.

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.

Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.

Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136. Review.

PMID:
28847797
8.

Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.

Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A.

Int J Cardiol. 2016 Jun 1;212:29-36. doi: 10.1016/j.ijcard.2016.02.134. Epub 2016 Mar 10. Review.

PMID:
27017118
9.

DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.

Bonora E, Cigolini M.

Nutr Metab Cardiovasc Dis. 2016 Apr;26(4):273-84. doi: 10.1016/j.numecd.2016.03.002. Epub 2016 Mar 12. Review.

PMID:
27038847
10.

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH.

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):700-710. doi: 10.2215/CJN.06080616. Epub 2017 Mar 2. Review.

11.

Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.

Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS.

J Am Coll Cardiol. 2017 Aug 15;70(7):883-893. doi: 10.1016/j.jacc.2017.07.001. Review.

12.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Med. 2017 Jun;130(6S):S4-S17. doi: 10.1016/j.amjmed.2017.04.004. Review.

13.

Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.

Busch RS, Kane MP.

Postgrad Med. 2017 Sep;129(7):686-697. doi: 10.1080/00325481.2017.1342509. Epub 2017 Jun 28.

PMID:
28657399
14.

Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.

Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG.

Curr Pharm Des. 2018;24(17):1879-1886. doi: 10.2174/1381612824666180604113653.

PMID:
29865997
15.

Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.

Naing S, Poliyedath A, Khandelwal S, Sigala T.

Postgrad Med. 2016 Nov;128(8):822-827. Epub 2016 Oct 25. Review.

PMID:
27701934
16.
17.

Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action.

Schernthaner-Reiter MH, Schernthaner G.

Expert Rev Endocrinol Metab. 2016 May;11(3):281-296. doi: 10.1586/17446651.2016.1151783. Epub 2016 Mar 7.

PMID:
30058933
18.

A review on cardiovascular effects of newer hypoglycaemic medications.

Cutshall BT, Twilla JD, Olinger AS, Oliphant CS.

Ann Med. 2017 Nov;49(7):603-612. doi: 10.1080/07853890.2017.1335428. Epub 2017 Jun 9. Review.

PMID:
28540743
19.

Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus.

Purga SL, Sidhu M, Farkouh M, Schulman-Marcus J.

Cardiovasc Drugs Ther. 2017 Aug;31(4):459-470. doi: 10.1007/s10557-017-6750-1. Review.

PMID:
28871349
20.

Glucagon and heart in type 2 diabetes: new perspectives.

Ceriello A, Genovese S, Mannucci E, Gronda E.

Cardiovasc Diabetol. 2016 Aug 27;15(1):123. doi: 10.1186/s12933-016-0440-3. Review.

Supplemental Content

Support Center